Afoxolaner has emerged as an important active pharmaceutical ingredient in the global veterinary healthcare market, particularly within the growing segment of companion animal parasiticides. The market has witnessed strong momentum from 2023 to 2025, driven by FDA approvals, the increasing adoption of combination therapies, and rising demand for advanced parasite-prevention products for dogs.
One of the most significant developments occurred in July 2023, when Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) approved NexGard® PLUS, a beef-flavored chewable tablet containing afoxolaner, moxidectin, and pyrantel. The product was developed as a comprehensive monthly oral treatment designed to protect dogs against a broad range of internal and external parasites. This approval represented a major advancement in the veterinary parasiticide segment by combining flea, tick, heartworm, hookworm, and roundworm protection into a single convenient therapy.
The launch of NexGard® PLUS strengthened Boehringer Ingelheim’s companion animal health portfolio and expanded the commercial reach of the NexGard franchise globally. The product specifically addresses growing demand from veterinarians and pet owners for simplified treatment solutions that improve compliance while offering broad-spectrum protection. Convenience has become a major factor in pet healthcare, and chewable oral products are increasingly preferred over topical treatments due to ease of administration and improved owner adherence.
Afoxolaner, which belongs to the isoxazoline class of parasiticides, functions by targeting the nervous system of fleas and ticks, leading to rapid parasite elimination. Its inclusion in combination therapies has enhanced its market value, particularly when paired with moxidectin and pyrantel to extend efficacy against internal parasites. This multi-mechanism approach has made afoxolaner-based products highly competitive in the global veterinary therapeutics market.
Further regulatory developments were reported in 2025, when FDA records confirmed continued approval activity related to afoxolaner-containing products. According to FDA veterinary medicine data, products containing Afoxolaner, Moxidectin, and Pyrantel Pamoate received recognition under NADA application 141-554, with an approval date of June 3, 2025. The approval reinforced the product’s established position in canine healthcare and demonstrated sustained regulatory confidence in combination oral parasite therapies.
The veterinary pharmaceuticals industry is increasingly focused on preventive healthcare strategies, especially in developed pet care markets such as the United States and Europe. Rising awareness regarding vector-borne diseases, including tick-related infections and heartworm disease, has significantly increased demand for reliable preventive treatments. Products containing afoxolaner are benefiting from these trends due to their long-lasting efficacy, broad parasite coverage, and favorable administration profile.
In addition, the growing humanization of pets and rising expenditure on companion animal healthcare continue to support market growth. Pet owners are increasingly seeking premium veterinary products that offer comprehensive protection and reduce the frequency of multiple treatments. This trend has encouraged pharmaceutical companies to invest in advanced combination therapies and next-generation chewable formulations.
Overall, the Afoxolaner market (2023–2025) reflects strong growth potential driven by regulatory approvals, innovation in oral combination therapies, and increasing focus on preventive veterinary medicine. FDA-approved products such as NexGard® PLUS continue to strengthen the market position of afoxolaner-based treatments while supporting the broader expansion of the global companion animal healthcare industry.
